Journal of Clinical Oncology
Articles in this Issue
Analysis of the results of whole-exome sequencing of paired samples in patients of the Eurasian population with triple-negative breast cancer and their impact on clinical outcomes.
e12605 Background: While standard practice focuses on germline mutations, our study identifies clinically relevant somatic...
Breast care outcomes and infectious disease: Insights from COVID-19.
e13086 Background: Adverse inpatient outcomes with COVID-19 have been well characterized for aggregations of all cancer ty...
HLA-A*01 as a biomarker of poor outcome in patients treated with immune checkpoint inhibitors.
e14547 Background: Despite advances in immune checkpoint inhibition, clinical responses remain highly variable, highlighti...
Multi-omic profiling to identify RNA-protein concordance and post-transcriptional dysregulation in HER2+ breast cancer.
573 Background: Standard HER2 testing relies on single-modality assays, such as immunohistochemistry (IHC) for protein ove...
Comparative efficacy of PD-1 versus PD-L1 inhibitors in metastatic colorectal cancer: A real-world propensity score–matched study.
e15599 Background: The treatment of microsatellite instability-high (MSI-H) metastatic colorectal cancers (mCRC) has evolv...
Rapid digital patient-derived organoid testing for guiding therapy in patients with metastatic breast cancer receiving antibody drug conjugates (ADCs).
1033 Background: MBC remains incurable despite recent incorporation of ADCs. The optimal sequencing of FDA-approved ADCs s...
First-in-human PET/CT imaging with 68Ga-AKY-2519, a B7-H3 targeted miniprotein radioconjugate, to demonstrate tumor uptake and normal tissue exposure across various advanced solid tumors.
3098 Background: 68Ga-AKY-2519 is a miniprotein radioconjugate developed by Aktis Oncology that targets B7-H3 (CD276) whic...
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
e19516 Background: Teclistamab, a BCMA×CD3 bispecific antibody, demonstrates significant efficacy in relapsed/refractory m...
Development and testing of an ex vivo, live tumor fragment platform for the prediction of immune checkpoint inhibitor response and relationship to approved biomarkers.
2646 Background: Immune checkpoint inhibitors (ICIs) have transformed the management of many advanced cancers but identify...
Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials.
e13061 Background: Resistance to endocrine therapy remains a major clinical challenge in estrogen receptor–positive (ER+),...
Geographic disparities in hepatocellular carcinoma incidence in the United States, 2001–2022.
e16281 Background: Hepatocellular carcinoma (HCC) incidence in the United States has recently stabilized or declined; howe...
Effects of yttrium-90 radioembolization on epigenomic immune remodeling in hepatocellular carcinoma: Profiled by blood-based 3D genome conformation assay.
e16273 Background: Yttrium-90 (Y-90) radioembolization for intermediate-stage hepatocellular carcinoma (HCC) has been show...
Biomarkers to predict anthracycline-induced cardiotoxicity in adult hematologic malignancies: A systematic review.
e24012 Background: Anthracyclines are a mainstay of treatment in hematologic malignancies, particularly in lymphomas and a...
Shifting dietary drivers of colorectal cancer mortality in the United States: A 33-year Global Burden of Disease analysis.
3663 Background: Early-onset colorectal cancer (EOCRC; ages 15–49 years) mortality is increasing in the United States. How...
Molecular remission after tyrosine kinase inhibitor cessation in chronic myeloid leukemia (CML): A systematic review and meta-analysis.
e18601 Background: Tyrosine kinase inhibitors (TKIs) have transformed the management of chronic myeloid leukemia (CML), en...
Epidemiology of sarcoma in Syria: A retrospective study from the national referral center.
e23504 Background: The Syrian conflict has devastated healthcare infrastructure, creating a critical data gap in cancer ep...
Impact of consensus-based feature selection on machine learning performance for metastatic lung cancer prediction in resource-limited settings.
e20519 Background: In low- and middle-income countries (LMICs), lung cancer is frequently diagnosed at advanced or metasta...
Overall survival of patients with mucosal melanoma in the US before and after the advent of PD-1 based immune checkpoint inhibitor treatment.
9546 Background: Mucosal melanoma (MM) is a rare, aggressive melanoma subtype with poor survival. Prior to 2010, systemic...
Multi-omics discovery and clinical validation of COL1A2 alternative splicing isoforms as liquid biopsy markers for metastasis surveillance in osteosarcoma.
3055 Background: Osteosarcoma (OS) is characterized by early metastatic dissemination, yet the lack of sensitive and tumor...
<i>SH2B3</i> in myeloid neoplasms: Potential pathogenic role of variants of uncertain significance.
e18584 Background: SH2B3 is an adaptor protein that downregulates JAK-STAT signaling by binding JAK2. Loss-of-function mut...
Sensitivity of portal vein ctDNA versus peripheral blood in predicting postoperative liver metastasis adjuvant therapy in colorectal cancer.
3139 Background: The detection of minimal residual disease (MRD) in colorectal cancer (CRC) is crucial for predicting post...
Machine learning approach for prediction of immune-related pneumonitis.
12153 Background: Immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI) substantially co...
ARTEMIDE-Biliary02: A phase 3, randomized, global study of rilvegostomig or durvalumab with chemotherapy as first-line (1L) treatment for advanced biliary tract cancer (BTC).
TPS4253 Background: Biliary tract cancer (BTC) is the second most common hepatic malignancy, comprising 15% of liver tumor...
Machine learning risk stratification in a US-based database to identify subgroups of patients with head and neck cancer who benefit from adding chemotherapy to pembrolizumab.
e18007 Background: First-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incl...
Safety and efficacy of dostarlimab monotherapy as first-line treatment in programmed cell death-ligand 1–positive recurrent/metastatic head and neck squamous cell carcinoma: Results from a phase 2 trial.
6037 Background: The use of immune checkpoint inhibitors (ICIs) in recurrent/metastatic (R/M) head and neck squamous cell...